- Home
- ARTV vs FGEN Comparison
ARTV vs FGEN Comparison
Compare ARTV & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTV
- FGEN
- Stock Information
- Founded
- ARTV 2019
- FGEN 1993
- Country
- ARTV United States
- FGEN United States
- Employees
- ARTV N/A
- FGEN N/A
- Industry
- ARTV
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- ARTV
- FGEN Health Care
- Exchange
- ARTV NYSE
- FGEN Nasdaq
- Market Cap
- ARTV 41.2M
- FGEN 33.5M
- IPO Year
- ARTV 2024
- FGEN 2014
- Fundamental
- Price
- ARTV $3.60
- FGEN $7.45
- Analyst Decision
- ARTV Strong Buy
- FGEN Strong Buy
- Analyst Count
- ARTV 8
- FGEN 1
- Target Price
- ARTV $18.14
- FGEN $250.00
- AVG Volume (30 Days)
- ARTV 373.8K
- FGEN 48.5K
- Earning Date
- ARTV 08-28-2025
- FGEN 08-05-2025
- Dividend Yield
- ARTV N/A
- FGEN N/A
- EPS Growth
- ARTV N/A
- FGEN N/A
- EPS
- ARTV N/A
- FGEN N/A
- Revenue
- ARTV N/A
- FGEN $6,996,000.00
- Revenue This Year
- ARTV N/A
- FGEN N/A
- Revenue Next Year
- ARTV N/A
- FGEN N/A
- P/E Ratio
- ARTV N/A
- FGEN N/A
- Revenue Growth
- ARTV N/A
- FGEN N/A
- 52 Week Low
- ARTV $1.47
- FGEN $4.50
- 52 Week High
- ARTV $17.31
- FGEN $33.49
- Technical
- Relative Strength Index (RSI)
- ARTV N/A
- FGEN 55.79
- Support Level
- ARTV N/A
- FGEN $7.31
- Resistance Level
- ARTV N/A
- FGEN $7.82
- Average True Range (ATR)
- ARTV 0.00
- FGEN 0.59
- MACD
- ARTV 0.00
- FGEN 0.10
- Stochastic Oscillator
- ARTV 0.00
- FGEN 69.35
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.